Tarsus Pharmaceuticals, Inc. $TARS Shares Sold by Assenagon Asset Management S.A.

Assenagon Asset Management S.A. lessened its holdings in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) by 9.6% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,127,730 shares of the company’s stock after selling 120,224 shares during the period. Assenagon Asset Management S.A. owned approximately 2.66% of Tarsus Pharmaceuticals worth $92,339,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. Deep Track Capital LP grew its stake in Tarsus Pharmaceuticals by 71.4% during the 3rd quarter. Deep Track Capital LP now owns 3,000,000 shares of the company’s stock worth $178,290,000 after buying an additional 1,250,000 shares during the last quarter. Norges Bank purchased a new stake in Tarsus Pharmaceuticals in the second quarter valued at about $19,095,000. MPM Bioimpact LLC purchased a new stake in Tarsus Pharmaceuticals in the second quarter valued at about $13,834,000. TimesSquare Capital Management LLC acquired a new stake in Tarsus Pharmaceuticals in the third quarter worth about $15,898,000. Finally, Capricorn Fund Managers Ltd acquired a new stake in Tarsus Pharmaceuticals in the third quarter worth about $14,264,000. Institutional investors and hedge funds own 90.01% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on TARS shares. Weiss Ratings restated a “sell (d-)” rating on shares of Tarsus Pharmaceuticals in a report on Thursday, January 22nd. Barclays began coverage on shares of Tarsus Pharmaceuticals in a research note on Monday, December 8th. They issued an “overweight” rating and a $100.00 target price for the company. Lifesci Capital upgraded shares of Tarsus Pharmaceuticals to a “strong-buy” rating in a research note on Monday, March 16th. Zacks Research cut shares of Tarsus Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Wednesday, February 25th. Finally, The Goldman Sachs Group reiterated a “neutral” rating and set a $68.00 price objective on shares of Tarsus Pharmaceuticals in a research note on Thursday, February 5th. Two research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Tarsus Pharmaceuticals presently has an average rating of “Moderate Buy” and an average target price of $91.83.

Insider Buying and Selling at Tarsus Pharmaceuticals

In other news, General Counsel Bryan Wahl sold 4,231 shares of the company’s stock in a transaction on Thursday, March 19th. The shares were sold at an average price of $67.00, for a total value of $283,477.00. Following the sale, the general counsel directly owned 63,959 shares of the company’s stock, valued at $4,285,253. This represents a 6.20% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Elizabeth Yeu Lin sold 390 shares of the firm’s stock in a transaction on Thursday, March 19th. The stock was sold at an average price of $67.00, for a total transaction of $26,130.00. Following the transaction, the insider directly owned 23,308 shares of the company’s stock, valued at approximately $1,561,636. This trade represents a 1.65% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 79,391 shares of company stock worth $5,432,035. Corporate insiders own 8.97% of the company’s stock.

Tarsus Pharmaceuticals Trading Down 1.5%

Shares of NASDAQ:TARS opened at $63.15 on Wednesday. The company has a quick ratio of 3.82, a current ratio of 3.85 and a debt-to-equity ratio of 0.21. Tarsus Pharmaceuticals, Inc. has a 52-week low of $38.51 and a 52-week high of $85.25. The stock has a market cap of $2.69 billion, a price-to-earnings ratio of -38.98 and a beta of 0.55. The business has a 50-day moving average price of $68.64 and a 200-day moving average price of $70.47.

Tarsus Pharmaceuticals (NASDAQ:TARS) last issued its earnings results on Monday, February 23rd. The company reported ($0.20) EPS for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.01). Tarsus Pharmaceuticals had a negative net margin of 14.72% and a negative return on equity of 19.63%. The firm had revenue of $151.67 million during the quarter, compared to analysts’ expectations of $144.56 million. Equities analysts predict that Tarsus Pharmaceuticals, Inc. will post -3.17 EPS for the current year.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for diseases of the eye and ocular surface. The company’s research platform centers on neuro‐effector modulation to address underlying disease mechanisms rather than solely treating symptoms. Tarsus’s lead candidate, OC-01 (varenicline solution), is an intranasal formulation in Phase 3 development for the treatment of dry eye disease, a condition affecting millions worldwide and associated with significant patient discomfort and reduced quality of life.

In addition to its dry eye program, Tarsus is advancing preclinical and early‐stage programs targeting other ophthalmic indications, including allergic conjunctivitis and retinal disorders.